期刊
CANCER TREATMENT REVIEWS
卷 88, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2020.102047
关键词
Clinical trials; COVID-19; Drug development
类别
资金
- Dutch Cancer Society [RUG 2014-6691]
- Conacyt [381543]
The COVID-19 pandemic affected many activities in the healthcare system including oncology drug development. Clinical trial recruitment was temporary halted in many centres to reduce patients and healthcare workers' potential exposure to the virus. Conversely, to continue offering treatments for patients already on effective therapies, multiple actions were timely put in place, resulting in simplification of trial-related procedures for patients and clinicians' best interest, reduction of the operational burden and effective communication. Here, we suggest maintaining effective measures for future trial simplification and to expedite drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据